Tarsus, LianBio to develop, commercialize TP-03 in Greater China
Tarsus Pharmaceuticals and LianBio have entered into a strategic partnership to develop and market TP-03 for the treatment of meibomian gland dysfunction and Demodex blepharitis in Greater China, according to a press release.
LianBio gains exclusive rights to develop and commercialize TP-03 (lotilaner ophthalmic solution 0.25%) in Greater China and will pay Tarsus $15 million upfront, the release said.
Tarsus may receive up to $185 million if it meets development and commercialization milestones, including $10 million by June 30 and $45 million over the next year for near-term clinical milestones, the release said. In addition, Tarsus may receive “tiered low double-digit royalties” based on TP-03 sales in Greater China and a minority stake in LianBio Ophthalmology depending on the milestone achievements.